Dermaliq Therapeutics

Dermaliq’s mission is to develop a new generation of high-quality and user-friendly products with maximum efficacy and safety. Dermaliq’s transformative hyliQ® technology ushers in a new generation of topical products which offer not only superior dermal drug delivery for conditions like psoriasis and eczema but targeted delivery deep into hair follicles and sebaceous glands. Our goal is to establish a comprehensive pipeline of next-generation topical drugs and medical skin care products based on our proprietary hyliQ® technology. Dermaliq Therapeutics, Inc.,1201 North Market Street, Suite 111,Wilmington, DE 19801, USA. Dermaliq Therapeutics GmbHIm Neuenheimer Feld 515 69120 Heidelberg, Germany. Our unique “hyliQ®” technology overcomes the “delivery barrier” and for the first time enables the adsorption of multiple attractive active ingredients and drugs into the follicle and skin, enabling the development of “first in class” and “best in class” treatment options. Skin and hair disorders are a leading cause of nonfatal disease burden worldwide and have a significant impact on a person’s well-being, mental health, ability to function, and social participation. Topical, localized delivery of active ingredients to skin and scalp is the preferred route of treatment in most patients, reducing the risk of systemic side effects.